- In patients with moderate to severe atopic dermatitis, dupilumab is associated with sustained clinical improvement and a stable safety profile, according to a 3-year open-label extension study (LIBERTY AD OLE).
Why this matters
- These results suggest that dupilumab is an appropriate continuous treatment choice in this patient group.
- Mean self-reported drug adherence was 98.2%.
- At week 148, mean improvement in the Eczema Area and Severity Index was −95.4% compared with baseline.
- At week 148, mean improvement in the Pruritus Numerical Rating Scale was −65.4% compared with baseline.
- The rate of adverse events was 270.1 per 100 patient-years.
- The rate of serious adverse events was 6.92 per 100 patient-years.
- The most common adverse events (≥5% of patients) were nasopharyngitis, atopic dermatitis, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reaction.
- Of 2677 patients with atopic dermatitis originally enrolled and treated, 347 reached week 148 and were analyzed for efficacy and safety.
- Funding: Sanofi, Regeneron Pharmaceuticals, Inc.
- Open-label study.
- Nonapproved dosage was used.